USC.edu
Are You a Patient?

Jeffrey A. Kahn, MD

Professor of Clinical Medicine, Acting Chief, Division of GI and Liver Diseases

Image of Jeffrey A. Kahn, MD
Is this your profile? Click to edit
Request an Appointment
Phone +1 323 442 5908
Email [email protected]
CTSI Profile

Overview

Dr. Kahn is the medical director of the USC Liver Transplant Program. He received fellowship training in gastroenterology and transplant hepatology from the Keck School of Medicine and Cedars-Sinai Medical Center. He is board certified in internal medicine, gastroenterology and transplant hepatology.

Dr. Kahn’s primary research interests are in liver transplantation, hepatocellular carcinoma and viral hepatitis. He has written and co-authored several abstracts and peer-reviewed articles on various topics such as chronic hepatitis C and liver transplantation. He is also a distinguished lecturer.

Awards

  • Alpha Omega Alpha, 1990

Publications

  • Excess liver transplant waitlist mortality for patients with primary biliary cholangitis under MELD-Na allocation. Clin Transplant. 2022 02; 36(2):e14527.. View in PubMed
  • Transfusion-free Retransplantation for Post-liver Transplantation Hepatic Artery Thrombosis: How Much Augmentation Is Too Much? Transplant Direct. 2021 Nov; 7(11):e776. Mulgaonkar A, Horwich B , Kim B . View in PubMed
  • We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases. Hepatology. 2021 11; 74(5):2876-2887.. View in PubMed
  • Use of Hepatitis B Virus-Positive Organs in Organ Transplantation. Clin Liver Dis. 2021 11; 25(4):841-857.. View in PubMed
  • Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S. HPB (Oxford). 2022 02; 24(2):234-243.. View in PubMed
  • Autoimmune hepatitis triggered by COVID-19. Intern Med J. 2021 Jul; 51(7):1182-1183.. View in PubMed
  • A Healthy Liver After SVR: Food for Thought. Dig Dis Sci. 2021 06; 66(6):1778-1779.. View in PubMed
  • Impact of Morbid Obesity on Liver Transplant Candidacy and Outcomes: National and Regional Trends. Transplantation. 2021 05 01; 105(5):1052-1060.. View in PubMed
  • Applying the original model for end-stage liver disease score rather than the model for end-stage liver disease-Na score for risk stratification prior to transjugular intrahepatic portosystemic shunt procedures. Eur J Gastroenterol Hepatol. 2021 04 01; 33(4):541-546.. View in PubMed
  • The use of organs from hepatitis C virus-viremic donors into uninfected recipients. Curr Opin Organ Transplant. 2020 12; 25(6):620-625.. View in PubMed

Similar People